1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. DIANTHUS THERAPEUTICS INC

Dianthus Therapeutics Inc

XNAS: DNTH

Download real time

20.74 -1.23 (-5.60%)

38.58% Fall from 52W High

269.7K XNAS Volume

High vol.+loss this week

XNAS 18 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
5S
13W
2O
2T
666.3

Market Cap

Below industry Median
-7.8

PE TTM

Negative PE TTM
0.1

PEG TTM

PEG TTM is less than 1
1.9

Price to Book

Below industry Median
-0.1

Beta 1Year

Very Low volatility
Board Meeting
The next board meeting for Dianthus Therapeutics Inc is on 21 Mar 2025 for the purpose of Dianthus Therapeutics Inc Fourth Quarter Earnings Results for 2024 See details


Insider Trading disclosures for Dianthus Therapeutics Inc

The latest disclosure was made by Sujay R. Kango in Dianthus Therapeutics Inc where a trade of 25,000 Stock Option (Right to Buy) done was reported to US exchanges on March 4, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Sujay R. Kango Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 25,000 25,000 - - Stock Option (Right to Buy)
Simrat Randhawa CHIEF MEDICAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 150,000 150,000 - - Stock Option (Right to Buy)
Ryan Savitz CFO & CBO Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 150,000 150,000 - - Stock Option (Right to Buy)
Adam M. Veness SVP, General Counsel and Sec. Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 100,000 100,000 - - Stock Option (Right to Buy)
Edward G. Carr CHIEF ACCOUNTING OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 60,000 60,000 - - Stock Option (Right to Buy)
Marino Garcia Director, CEO AND PRESIDENT Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 340,000 340,000 - - Stock Option (Right to Buy)
Steven Joseph Romano Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2024 22,000 22,000 - - Stock Option (Right to Buy)
Edward G. Carr CHIEF ACCOUNTING OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 60,000 60,000 - - Stock Option (Right to Buy)
Adam M. Veness SVP, General Counsel and Sec. Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 75,000 75,000 - - Stock Option (Right to Buy)
Simrat Randhawa CHIEF MEDICAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 100,000 100,000 - - Stock Option (Right to Buy)
Ryan Savitz CFO & CBO Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 100,000 100,000 - - Stock Option (Right to Buy)
Anne M. McGeorge Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 11,000 11,000 - - Stock Option (Right to Buy)
Marino Garcia Director, CEO AND PRESIDENT Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 243,000 243,000 - - Stock Option (Right to Buy)
Jonathan Violin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 11,000 11,000 - - Stock Option (Right to Buy)
Paula Soteropoulos Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 11,000 11,000 - - Stock Option (Right to Buy)
Alison F. Lawton Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 11,000 11,000 - - Stock Option (Right to Buy)
Leon O. Moulder Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 11,000 11,000 - - Stock Option (Right to Buy)
Marino Garcia Director, CEO AND PRESIDENT Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jan 2024 275,000 275,000 - - Stock Option (Right to Buy)
Adam M. Veness SVP, General Counsel and Sec. Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jan 2024 110,000 110,000 - - Stock Option (Right to Buy)
Simrat Randhawa CHIEF MEDICAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jan 2024 120,000 120,000 - - Stock Option (Right to Buy)
Ryan Savitz CHIEF FINANCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jan 2024 120,000 120,000 - - Stock Option (Right to Buy)
Edward G. Carr CHIEF ACCOUNTING OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jan 2024 80,000 80,000 - - Stock Option (Right to Buy)
Lei Meng Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jan 2024 1,833,333 1,833,333 - - Pre-Funded Warrants (Right to Buy)
Lei Meng Director Grant, award, or other acquisition of securities at price $ 12.00 per share. 22 Jan 2024 1,500,000 2,717,554 - 12 18,000,000 Common Stock
Leon O. Moulder Director Grant, award, or other acquisition of securities at price $ 12.00 per share. 22 Jan 2024 166,667 1,436,745 - 12 2,000,004 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters